Editorial
This week, let’s dive into the exciting world of Pharma, shall we? As we continue to navigate through the pandemic, the pharma sector has been under the scanner like never before.
In 2023, we’re expecting to see some major developments in the industry. However, it’s not all smooth sailing. The sector is facing a range of headwinds, from inflation and talent shortages to increasing competition and patent expiries.
One of the major trends we’re seeing is decentralized trial structures, which will require pharma companies to focus more closely on cybersecurity and protected health information (PHI) while managing costs. Additionally, the world of cancer vaccination is taking centre stage, with personalized medicine and innovative R&D in the spotlight.
But what really caught our attention are the latest medical devices and technologies that are likely to make a big splash this year. From skin patches that manage diseases to emotion AI that can detect your mood, to smart TVs that offer remote care, and even affordable vein scanners that make needle pricks a thing of the past, the future of healthcare is looking mighty impressive.
In this issue of This Week in Consulting, we have covered a lot — the strategies that will help pharma companies navigate this evolving world, the changing financing models to fund research and innovations, the latest breakthroughs in cancer vaccination and more!
So, dive right in and enjoy your read. And don’t forget to share your feedback with us.
Laurent THOMAS
Chairman Consulting Quest
This week’s must read
In This Week in Consulting, we have covered a lot — the strategies that will help pharma companies navigate this evolving world, the changing financing models to fund research and innovations, the latest breakthroughs in cancer vaccination and more!
PwC has released a report highlighting six key trends that will shape the pharmaceutical industry in 2023 and beyond. The trends include patient-centricity, digital transformation, data analytics, emerging markets, supply chain resilience, and sustainability. The report notes that companies that successfully navigate these trends will be better positioned to meet evolving patient needs, leverage new technologies, and capture growth opportunities in a rapidly changing industry.
This week’s media
This video features seven medical innovations that are simply mind-blowing. In this video, The Medical Futurist talks about the kind of stuff that used to be straight out of sci-fi movies. But now it’s real! We’ve got everything from skin patches that manage diseases to emotion AI that can detect your mood, to smart TVs that offer remote care. And don’t forget about those affordable vein scanners – no more painful needle pricks! Take a sneak peek into the future of healthcare!
Thought Leadership
This new report by ZS, a global consulting firm, has highlighted the potential for personalized medicine and precision oncology in the development of cancer vaccines. The report explores the current state of cancer vaccine research and development and argues that personalized cancer vaccines could revolutionize cancer treatment. It also highlights key challenges and opportunities for pharma companies looking to invest in cancer vaccine R&D.
This article by Eradigm highlights the growing significance of royalty financing in the pharmaceutical industry. The article examines Royalty Pharma, a company that owns stakes in a quarter of all blockbuster drugs and has pioneered the use of royalty financing to support drug development. The model offers benefits to both investors and pharma companies and has become an attractive alternative to traditional financing methods.
The new report by IBM highlights six strategies that life sciences companies should consider to drive innovation and growth over the next few years. The report focuses on digital transformation, data-driven insights, patient-centricity, partnerships and ecosystems, supply chain resiliency, and sustainability. It argues that companies that successfully leverage these strategies will be well-positioned to thrive in an increasingly complex and competitive industry.
The COVID-19 pandemic has disrupted the pharmaceutical industry’s operations, but also spurred innovation and accelerated digital transformation, according to a report by McKinsey. The report emphasizes the need for pharma companies to develop agile and resilient supply chains, leverage digital technologies to improve operations and patient outcomes, and collaborate across the ecosystem to enhance supply chain security and resilience.
This week’s consulting news selection
Argon & Co, a global management consulting firm, has announced the expansion of its logistics service offering in New Zealand. The move aims to meet the growing demand for logistics consulting services in the country’s fast-growing e-commerce and supply chain industries. The expansion will enable the company to provide end-to-end logistics solutions to its clients in New Zealand.|@Argon & Co
Accenture, a global professional services firm, has appointed Alan Jope, the CEO of Unilever, to its Board of Directors, effective immediately. Jope will bring his expertise in consumer goods, sustainability, and leadership to the board. Accenture’s chairman has said that Jope’s experience aligns well with the company’s focus on creating value for clients and driving sustainable growth.|@Accenture
Mercer, a global consulting firm, has appointed Jennifer Kruse as the new leader for its US Outsourced Chief Investment Officer (OCIO) business. Kruse will oversee the delivery of OCIO services to institutional clients, with a focus on driving growth, innovation, and client satisfaction.|
Infosys has partnered with the Department of Youth Affairs in India to launch a program that will support female athletes with training, mentoring, and financial support. The program aims to help aspiring women athletes overcome challenges and achieve their full potential in sports.|
Laurent is the Chairman and Co-founder of Consulting Quest. Focused on greater value creation, and being thoroughly familiar with Consulting, Laurent has sourced and sold millions of dollars worth of Consulting over the course of his career. Prior to joining Consulting Quest, Laurent was Executive Vice President Oil and Gas at Solvay and Senior Partner Transformation at Oliver Wyman.
